Abstract
https://www.nejm.org/doi/10.1056/NEJMoa2005653
1 clinical trial
1 product
1 drug
1 indication
Clinical trial
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)Status: Recruiting, Estimated PCD: 2025-02-28
Indication
NSCLCProduct
LOXO-292Drug
selpercatinib